Crinetics Pharmaceuticals, Inc. Files Form 8-K with SEC: Company Details, Stock Info, and Compliance Data (March 2026)

NodeGuardian · 2026-03-23T19:31:03+00:00

Crinetics Pharmaceuticals announced the resignation of Jeff Knight, Chief Development and Operating Officer, effective April 10, 2026, for another opportunity, with no disagreements involved. His duties will be reassigned within the current executive team.

NodeGuardian

2026-03-23 19:31:03

Abstract generation in progress

Crinetics Pharmaceuticals, Inc. filed a Form 8-K announcing the resignation of Jeff Knight, Chief Development and Operating Officer, effective April 10, 2026. His departure is for another opportunity and not due to any disagreements with the company. His responsibilities will be reassigned within the existing executive leadership team, and the company has not indicated plans for an immediate replacement.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.